We conducted a genome-wide association study of 3090 sporadic prostate cancer patients and controls using the Affymetrix 10 000 SNP GeneChip. Initial screening of 40 prostate cancer cases and 40 non-cancer controls revealed 237 SNPs to be associated with prostate cancer (Po0.05). Among these SNPs, 33 were selected for further association analysis of 2069 men who had undergone a cancer-screening prostate biopsy. Results identified five loci as being significantly associated with increased prostate cancer risk in this larger sample (rs1930293, OR ¼ 1.
Introduction
Many putative susceptibility genes for prostate cancer have been identified by genetic studies of multicase prostate cancer families (reviewed by Schaid 1 ). Polymorphisms in some of these candidate genes, such as HPC1 (RNasel), HPC2 (ELAC), HPC17 and CAPB (MSR1), have also been shown to be associated with sporadic (unselected) prostate cancer. [2] [3] [4] However, most of these associations have not been replicated and the genetic data are currently insufficient for clinical use in risk assessment.
Recent advances in single-nucleotide polymorphism (SNP) genotyping technologies have made possible SNPbased genome-wide association analysis. [5] [6] [7] To date, this strategy has not been applied to the search for sporadic prostate cancer alleles. Because hereditary forms of prostate cancer do not differ histopathologically from sporadic prostate cancer 8 and due to the large number of potential phenocopies within linkage studies, 1 genes underpinning sporadic cancer may be similar to those identified by linkage analysis of multicase prostate cancer families. To address this possibility and search for gene variants associated with risk for sporadic prostate cancer, we conducted a genome-wide association screen for prostate cancer alleles in a cohort of men who had undergone prostate biopsy among men who were screened for prostate cancer using serum prostate specific antigen (PSA) levels.
Methods

Study subjects
This study design was selected to optimize matching of prostate cancer 'cases' (biopsy-proven prostate cancer) and 'controls' (no cancer on biopsy) and to ensure the absence of prostate cancer in the age-matched controls. Study subjects were drawn from a consecutive sample of 3270 eligible men referred between 1998 and 2005 to two Prostate Centers at the University of Toronto because of a PSA value greater than or equal to 4.0 ng ml À1 . 9 No subject had a previous history of cancer and all subjects underwent one or more prostate biopsies to determine the presence of cancer. All patients agreed to participate in this study after informed consent, approved by the local Research Ethics Board. Among the 3090 subjects enrolled in the study, 1494 (48.3%) were found to have cancer (cases) and 1636 (51.7%) had no cancer (controls) detected in one or more biopsies. We have previously examined many candidate genes in this population and the characteristics of the study subjects have been reported.
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Genome-wide analysis For the genome-wide survey, 40 men with high grade prostate cancer (Gleason Score 8 or more) and 40 cancerfree controls (all having at least two negative prostate biopsies) fulfilling the following criteria were randomly selected from the study cohort: (1) PSA level o10 ng ml À1 ; (2) Caucasian descent and (3) no family history of prostate cancer. The screen was performed using Affymetrix 10 K GeneChips which test 11 555 biallelic SNPs randomly distributed throughout the genome and with median and mean inter-marker physical distances of 105 and 210 kb, respectively, and average minor allele frequency of 0.25. Screens were performed using standard Affymetrix protocols, scanner and analysis software (V2.0).
SNP selection from GeneChip
We selected SNPs that were associated with prostate cancer at or below the P ¼ 0.05 significance level. Among those SNPs, markers showing one or more of the following properties were further pursued: (1) association involving two or more SNPs in physical proximity or linkage disequilibrium (LD) with one another; (2) location in or near a disease, neoplastic or biologicallyrelevant gene as ascertained through database searches and (3) association with P-valueso0.001.
We then genotyped the selected SNPs found by the GeneChip on 1088 additional cancer patients and 1072 controls (total n ¼ 2160) using the mass-spectrometrybased Sequenom MassArray System (San Diego, CA, USA). 9 Of the SNPs found to be positively associated with prostate cancer among the 2160 men, tagSNPs across each of the loci were selected from the International HapMap Database (http://www.hapmap.org) and genotyped the initial set of 2160 subjects, and an additional 930 subjects (total of 1454 cases and 1636 controls, total n ¼ 3090). Tag SNPs were selected using the multimarker method.
Data analysis
We compared the genotype frequencies of the selected SNPs between prostate cancer cases and non-cancer controls. Multivariate unconditional logistic regression analysis was used to calculate the adjusted odds ratio Selected tagSNPs were first examined for HardyWeinberg equilibrium (HWE) using a chi-squared goodness-of-fit test. Those found not to be in HWE were excluded from the analysis. LD patterns were characterized by calculating pair-wise D-prime and R-values. Of the selected tagSNPs in HWE and in LD, we conducted haplotype analysis among the SNPs to examine their relationship between prostate cancers. Haplotype frequencies were determined using an expectation-maximization algorithm. 12 We used the haplotype trend regression model with binomial response to estimate haplotype assignment to individuals using the HelixTree Genetic Analysis software program V4.3 (http:// www.goldenhelix.com, Bozeman, MT).
Results
The initial screen among 40 cases and 40 controls revealed 237 SNPs to be associated with prostate cancer at or below the P ¼ 0.05 significance level. Based on our SNP selection critieria, 33 of the 237 SNPs were selected and genotyped in 1088 additional cancer patients and 1072 controls (total n ¼ 2160). As shown in Tables 1 and 2 , results of this analysis revealed five of the 33 SNPs (all on different chromosomes) to be positively associated (Po0.05) with prostate cancer risk (adjusted ORs ranging from 1.2 to 1.7).
To further evaluate these findings, tagSNPs across each of these five loci were selected (9-15 locus À1 ) from the International HapMap Database. Using the multimarker method, we selected a total of 61 tagSNPs and genotyped the initial set of 1088 cases and 1072 controls, and an additional 366 cases and 564 controls (total n ¼ 3090). Among the 61 tagSNPs, 15 were not in Hardy-Weinberg equilibrium in the controls, and were excluded from further analysis.
Significant associations between tagSNPs and prostate cancer were found for four of the five regions studied (1q25, 2p12, 4p34 and 7p21), P-values ranging from 0.05 to 0.001 (Table 3) . However, only the tagSNPs at 1q25 and 7p21 were in LD with the referent (GeneChip) diseaseassociated SNP identified in the initial whole genome screen. We therefore chose to pursue these latter two associations by haplotype analysis.
For haplotype analyses, the two cancer-associated SNPs on chromosome 1q25, the tagSNP (rs4568789-A/ G) and a referent (GeneChip) SNP (rs1930293-G/A) were treated as a single haplotype block. For patients with the risk haplotype (rs1930293-G/rs4568789-A), the adjusted OR for prostate cancer was 2.7 (P ¼ 0.0003) relative to patients lacking this risk haplotype (Table 4) . Of the SNPs on chromosome 7p21, one tagSNP (rs13225697-C/ T) and the referent (GeneChip) SNP (rs2348763-A/C) were positively associated with prostate cancer risk. For Sporadic prostate cancer RK Nam et al patients with the variant haplotype (rs2348763-C/ rs13225697-C), the OR for prostate cancer was 0.8 (P ¼ 0.01) compared to patients without it. Patients with the common allele haplotype had an OR of 1.3 (P ¼ 0.0004) for prostate cancer (Table 4) .
Discussion
From a genome-wide screen among a large cohort of sporadic prostate cancer cases, strong associations with prostate cancer were found in loci found by past linkage analysis studies and microarray array studies. Haplotype analysis revealed significant associations of prostate cancer with two allele risk haplotypes on both chromosome 1q25 (adjusted OR of 2.7 for prostate cancer, P ¼ 0.0003), and chromosome 7p21 (adjusted OR of 1.3, P ¼ 0.0004). As linkage data have identified a putative prostate cancer gene on chromosome 1q25 (HPC1), and microarray data have revealed the ETV1 oncogene to be overexpressed in prostate cancer tissue, it appears that chromosome 1q25 and 7p21 may be sites of gene variants conferring risk for sporadic and inherited forms of prostate cancer. This study represents the first report of prostate cancer-associated alleles identified by a genome-wide association survey of sporadic prostate cancer cases. The disease-associated loci detected here are of particular interest as they map to regions identified by other approaches as likely sites of prostate cancer risk alleles. Additional studies will be required to define the potential disease causal alleles within each associated region and to screen for functional changes engendered by the disease-associated SNPs. Analysis with higher resolution GeneChips (up to 500 000 SNPs) may also serve to identify disease-causal SNPs within these regions or others.
The two prostate cancer-associated SNPs at chromosome 1q25 lie within a region (q24-q31) identified in several studies as a disease-relevant linkage interval in hereditary prostate cancer (HPC1). 13, 14 Cloning of this area identified a putative gene, a polymorphic variant of the RNAsel gene (1q25) to be linked by association to prostate cancer risk. 2 However, further case-control studies could not replicate the association. 9, 15 We previously showed that the Arg462Gln SNP (rs486907) of the RNAsel gene was not associated with increased prostate cancer risk among our cohort. 9 The rs4568789 and 1830293 SNPs are within 1000 kb of each other at 1q25, and rs1930293 lies within 200 kb of the RNAsel gene. From high-resolution physical and transcription mapping studies between 1q25 and q31, Carpten et al. identified at least 136 new STSs from the HPC1 region. 16 Thus, it is possible that the rs4568789/ rs1930293 SNPs may define a risk haplotype that contributes to risk for both sporadic and inherited forms of prostate cancer. 
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Our data also suggest that a locus at chromosome 7p21 confers risk for prostate cancer. Alterations of the ETV1 gene are rare in prostate cancer, but its promoter region has been shown to be regulated by androgens and the androgen receptor. 17 More interestingly, this region contains the ETV1 oncogene, a gene recently shown in several studies to be overexpressed in prostate cancer cells when fused with the TMPSSR2 gene. 18 The two Despite our positive findings, we did not find any associations with prostate cancer at the 8q24 locus. Three large, independent, genome-wide association studies have found strong links between SNPs within the 8q24 locus and prostate cancer risk. [19] [20] [21] In these studies, large gene chips (up to 550 K SNPs) were utilized, compared to our study using the 10 K SNP chip. It is likely that the density of our chip did not cover the 8q24 area. Further study of this important region will be necessary in our cohort.
While this study was initiated using a small sample cohort, the use of subsequent re-analyses incorporating much larger numbers of cases and controls and the detection of loci in regions already implicated in prostate cancer, suggest that the two major associations detected here are real and reflect the presence of prostate cancer variants at or near these loci. Further studies are needed to replicate and refine these data, but the current findings suggest that gene variants at the 1q25 and 7p21 loci may confer risk for both sporadic and inherited forms of prostate cancer. Sporadic prostate cancer RK Nam et al
